Effects of an ARB on Microcirculation in Essential Hypertension

Effects of an Angiotensin Receptor Antagonist Candesartan versus a calcium channel blocker Amlodipine on Microvascular Rarefaction, Endothelial Dysfunction and Microalbuminuria in Essential Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-005432-32-GB

Enrollment

Registered

2009-04-16

Start date

2009-06-02

Completion date

Unknown

Last updated

2015-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension MedDRA version: 14.1 Level: LLT Classification code 10004254 Term: Benign essential hypertension System Organ Class: 10047065 - Vascular disorders

Interventions

Product Name: Candesartan Product Code: Candesartan Pharmaceutical Form: Capsule INN or Proposed INN: CANDESARTAN CAS Number: 139481597 Concentration unit: mg milligram(s) Concentration type: up to Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with uncomplicated mild-to-moderate essential hypertension (sitting diastolic BP = 90 - =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Malignant or accelerated hypertension. 2. Serum creatinine >180 µmol/L 3. Ischaemic heart disease 4. Cerebrovascular disease 5. Impaired liver functions 6. Diabetes mellitus 7. Pregnancy or risk of pregnancy, or lactation 8. History of alcoholism, drug abuse or other problems that are likely to invalidate the informed consent. 9. Dark-skinned individuals (capillary microscopy can’t be performed).

Design outcomes

Primary

Measure	Time frame
Primary end point(s): The increase in maximal skin capillary density at the end of 8 weeks treatment.;Main Objective: To evaluate the effects of controlling blood pressure with candesartan 8-16 mg od versus amlodipine 5-10 mg od on microvascular capillary rarefaction in patients with mild-to-moderate essential hypertension.;Secondary Objective: To evaluate the effects of controlling blood pressure with candesartan 8-16 mg od versus amlodipine 5-10 mg od on pulse wave velocity, aortic augmentation index, and microalbuminuria.	—

Measure

Time frame

Primary end point(s): The increase in maximal skin capillary density at the end of 8 weeks treatment.;Main Objective: To evaluate the effects of controlling blood pressure with candesartan 8-16 mg od versus amlodipine 5-10 mg od on microvascular capillary rarefaction in patients with mild-to-moderate essential hypertension.;Secondary Objective: To evaluate the effects of controlling blood pressure with candesartan 8-16 mg od versus amlodipine 5-10 mg od on pulse wave velocity, aortic augmentation index, and microalbuminuria.

—

Countries

United Kingdom

Contacts

Public ContactJoint Research Office

St George's University of London

004402087254986

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026